[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100658310":3},{"organization":4,"outcomesModule":7,"designInfo":31,"detailedDescription":37,"studyPopulation":30,"armGroups":38,"interventions":55,"overallOfficials":65,"centralContacts":70,"locations":30,"responsibleParty":76,"collaborators":30,"id":80,"slug":81,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":30,"eligibilityCriteria":86,"healthyVolunteers":82,"sex":87,"minAge":88,"maxAge":30,"enrollmentInfo":89,"targetDuration":30,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":99,"overallStatus":103,"whyStopped":30,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":30},{"fullName":5,"class":6},"Assiut University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":30},[9],{"measure":10,"description":11,"timeFrame":12},"Incidence of postoperative endophthalmitis","Proportion of eyes that develop culture-proven or clinically diagnosed postoperative endophthalmitis.","1 month",[14,17,20,24,27],{"measure":15,"description":16,"timeFrame":12},"Mean best-corrected visual acuity","Mean best-corrected visual acuity (BCVA) in logMAR",{"measure":18,"description":19,"timeFrame":12},"Mean endothelial cell density","Mean corneal endothelial cell density (cells\u002Fmm²) measured by specular microscopy.",{"measure":21,"description":22,"timeFrame":23},"Mean anterior chamber cell grade","Mean grade of anterior chamber cells according to Standardization of Uveitis Nomenclature (SUN) criteria.","1 week",{"measure":25,"description":26,"timeFrame":23},"Incidence of postoperative corneal edema","Proportion of eyes with clinically significant postoperative corneal edema.",{"measure":28,"description":29,"timeFrame":12},"Mean central corneal thickness","Mean central corneal thickness in micrometers.",null,{"allocation":32,"interventionModel":33,"interventionModelDescription":30,"primaryPurpose":34,"observationalModel":30,"timePerspective":30,"maskingInfo":35},"RANDOMIZED","PARALLEL","PREVENTION",{"masking":36,"maskingDescription":30,"whoMasked":30},"NONE","Postoperative endophthalmitis is a serious complication of cataract surgery. Intracameral antibiotics are used to reduce this risk.\n\nThis study will randomly assign patients undergoing elective phacoemulsification to receive either intracameral levofloxacin, intracameral moxifloxacin, or no intracameral antibiotic (control). Patients will be followed for visual outcomes, anterior chamber inflammation, and corneal endothelial safety.",[39,45,51],{"label":40,"type":41,"description":42,"interventionNames":43},"Intracameral Levofloxacin","EXPERIMENTAL","Patients will receive 0.1 mL of preservative-free levofloxacin 0.5% injected into the anterior chamber at the end of phacoemulsification.",[44],"Drug: Levofloxacin",{"label":46,"type":47,"description":48,"interventionNames":49},"Intracameral Moxifloxacin","ACTIVE_COMPARATOR","Patients will receive 0.1 mL of preservative-free moxifloxacin 0.5% injected into the anterior chamber at the end of phacoemulsification.",[50],"Drug: Moxifloxacin",{"label":52,"type":53,"description":54,"interventionNames":30},"No Intracameral Antibiotic","NO_INTERVENTION","Patients will undergo standard phacoemulsification without any intracameral antibiotic injection.",[56,61],{"type":57,"name":58,"description":59,"armGroupLabels":60,"otherNames":30},"DRUG","Levofloxacin","0.1 mL of preservative-free levofloxacin 0.5% injected into the anterior chamber at the end of phacoemulsification.",[40],{"type":57,"name":62,"description":63,"armGroupLabels":64,"otherNames":30},"Moxifloxacin","0.1 mL of preservative-free moxifloxacin 0.5% injected into the anterior chamber at the end of phacoemulsification.",[46],[66],{"name":67,"affiliation":68,"role":69},"Mohamed s Abdel rahman, prof","Ophthalmology Department, Assiut University Hospitals","STUDY_CHAIR",[71],{"name":72,"role":73,"phone":74,"phoneExt":30,"email":75},"Sherly S Sobhy, Resident","CONTACT","01281224292","Sherly.21413@gmail.com",{"type":77,"investigatorFullName":78,"investigatorTitle":79,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"PRINCIPAL_INVESTIGATOR","Sherly Shamoun","Resident Physician, Department of Ophthalmology","100658310","intracameral-levofloxacin-versus-moxifloxacin-after-cataract-surgery-100658310",false,"NCT07850414","Intracameral Levofloxacin Versus Moxifloxacin After Cataract Surgery","Comparative Analysis of the Safety and Efficacy of Intracameral Injection of Levofloxacin and Moxifloxacin at the End of Cataract Surgery","Inclusion Criteria:\n\n* \\- Senile cataract scheduled for elective cataract surgery\n* Undergoing standard phacoemulsification with foldable posterior chamber IOL implantation\n* Healthy corneal endothelium with normal cell count on specular microscopy\n* Written informed consent\n* Willing and able to attend scheduled postoperative follow-up visits\n\nExclusion Criteria:\n\n* \\- Active ocular infection or inflammation\n* Complicated or traumatic cataract requiring non-standard surgical approach\n* Known hypersensitivity to levofloxacin or moxifloxacin\n* Unable or unwilling to comply with the postoperative follow-up schedule","ALL","18 Years",{"count":90,"type":91},93,"ESTIMATED","INTERVENTIONAL",[94],"NA","This randomized study aims to compare the safety and efficacy of intracameral levofloxacin versus intracameral moxifloxacin administered at the end of phacoemulsification cataract surgery.",[97,98],"Cataract","Postoperative Endophthalmitis",[100,101,58,62,102],"Intracameral antibiotic","Cataract surgery","Assiut","NOT_YET_RECRUITING","2026-09-24",{"date":106,"type":107},"2026-09-30","ACTUAL",{"date":109,"type":91},"2026-09-26",{"date":111,"type":91},"2028-02-25",{"name":5,"class":6}]